Posting fresh info about MS, for people with MS and their supporters

  • FDA details timeframe of Tysabri’s PML risk

    The brain infection risk from Biogen Idec’s multiple sclerosis drug Tysabri appears highest during the third year of treatment, U.S. health officials said in an updated warning [...]


    • Biogen Reports 2 New PML Cases in October

      The Cambridge, Massachusetts-based biotechnology company said in its latest monthly update that as of Oct. 1, there have been 70 confirmed cases of PML, up from 68 [...]


      • Five more cases of PML linked to Tysabri

        Biogen has reported five more cases of rare brain infection PML in patients taking Tysabari, the multiple sclerosis drug it jointly sells with Irish based Elan. This [...]


        • If caught early, Tysabri-PML not fatal for MS patients

          Alexandra Schroder, M.D., the lead investigator from Ruhr-University in Bochum, Germany points out that this is different for those who don’t have multiple sclerosis (MS) and get [...]


          • Biogen’s Tysabri Problems the Fault of European Docs?

            As mentioned in my last BNET Pharma posting, Biogen Idec’s key multiple sclerosis drug Tysabri had been linked to 23 worldwide cases of a potentially deadly brain [...]


            • Biogen Reports 2 More Cases of PML with Tysabri

              By THOMAS GRYTA Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan [...]


              • Elan and Biogen are in a Fight

                Elan starts legal action in drug row with Biogen By Andrew Jack Published: August 6 2009 22:34 | Last updated: August 6 2009 22:34 Elan has launched [...]


                • 11th Case of PML Reported With Tysabri

                  The 11the patient on Tysabri has developed a potentially deadly brain infection. This is what happened when three people who were on Tysabri and other medications for [...]


                  • Hot off the AAN Press: Tysabri Promotes Remyelination

                    July 4, 2009 Biogen Idec (NASDAQ: BIIB) and Elan Corporation (NYSE: ELN) announced results of a study demonstrating that Tysabri® (natalizumab) promoted regeneration and stabilization of damage [...]


                    • Biogen Reports 13th Case of PML

                      By KEITH J. WINSTEIN Biogen Idec Inc.’s disclosure of a debilitating brain infection in a patient taking its Tysabri multiple-sclerosis medicine sparked a selloff in shares of [...]


Feeds

Search


SUPPORT / Find out More


 

TAG / CLOUD

aan, alemtuzumab, avonex, betaseron, biogen, bioms medical corp, campath, ccsvi, cis, cladribine, clarity, cognitive dysfunction, copaxone, daclizumab, dirucotide, discovery, ectrims, elan, fampridine-sr, fatigue, fda, fda fast track status, fingolimod, fty-720, genzyme, gilenia, gilenya, interferons, laquinimod, merck, merck/serono, novartis, oral ms therapies, phase iii, pml, rebif, rrms, serono, smoking, spms, stem cells, teriflunomide, teva, therapy, tysabri

ARCHIVES / PAST ARTICLES



Follow me on Twitter
Friend me on Facebook
Subscribe by Email




Bookmark and Share


Wordpress Engine. Upstart Theme. Better Project.